4/24
10:45 am
nvcr
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Low
Report
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
4/10
09:08 am
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock, up previously from $25.00.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock, up previously from $25.00.
4/5
07:00 am
nvcr
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
Medium
Report
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
4/3
01:14 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Company from $49.00 to $42.00. They now have an "overweight" rating on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Company from $49.00 to $42.00. They now have an "overweight" rating on the stock.
4/1
01:42 pm
nvcr
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
Low
Report
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
4/1
07:00 am
nvcr
Novocure to Report First Quarter 2024 Financial Results
Low
Report
Novocure to Report First Quarter 2024 Financial Results
3/28
06:36 am
nvcr
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock? [Yahoo! Finance]
3/27
10:07 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.
Medium
Report
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.
3/27
02:11 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at HC Wainwright from $22.00 to $24.00. They now have a "neutral" rating on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at HC Wainwright from $22.00 to $24.00. They now have a "neutral" rating on the stock.
3/27
07:00 am
nvcr
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
High
Report
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
3/20
10:37 am
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at JPMorgan Chase & Co. from $15.00 to $17.00. They now have a "neutral" rating on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at JPMorgan Chase & Co. from $15.00 to $17.00. They now have a "neutral" rating on the stock.
3/13
11:38 am
nvcr
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect? [Yahoo! Finance]
Low
Report
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect? [Yahoo! Finance]
3/11
07:00 am
nvcr
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
Medium
Report
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
2/29
07:42 am
nvcr
Is NovoCure Limited (NASDAQ:NVCR) Worth US$16.0 Based On Its Intrinsic Value? [Yahoo! Finance]
Medium
Report
Is NovoCure Limited (NASDAQ:NVCR) Worth US$16.0 Based On Its Intrinsic Value? [Yahoo! Finance]
2/23
11:55 am
nvcr
NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/23
11:14 am
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at Evercore ISI from $14.00 to $15.00. They now have an "in-line" rating on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at Evercore ISI from $14.00 to $15.00. They now have an "in-line" rating on the stock.
2/22
02:30 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.
2/22
07:44 am
nvcr
NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
Medium
Report
NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
2/22
07:00 am
nvcr
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Medium
Report
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update